2024
Post-COVID-19 condition: systemic inflammation and low functional exercise capacity
de Castro G, Gama L, Ramos A, da Silva G, de Souza Teixeira A, Cunha-Neto E, de Souza H, Marie S, Talib L, Coelho V, Kalil J, de Araujo A, Ritto A, Belon A, Santos A, Barrére A, Sawamura M, Lamas C, Baldi B, Carvalho C, Kulikowski L, Damiano R, Imamura M, Neto J, Lira F, Otoch J, Miguel E, Battistella L, Forlenza O, Busatto G, Seelaender M. Post-COVID-19 condition: systemic inflammation and low functional exercise capacity. Frontiers In Nutrition 2024, 11: 1295026. PMID: 38549752, PMCID: PMC10973152, DOI: 10.3389/fnut.2024.1295026.Peer-Reviewed Original ResearchPost-COVID-19 conditionTimed Up and Go testUp-and-go testPhysical performance testsAcute COVID-19Low handgrip strengthFollow-up assessment 6Cross-sectional studySelf-reported symptomsFollow-up assessmentQuality of lifeDiagnosing pulmonary lesionsHandgrip strengthSerum cytokine profilesSerum cytokine levelsImpact of inflammationControl groupMCP-1 levelsIL-4 concentrationMale participantsHospital dischargeSymptom questionnaireSymptom groupsFemale participantsDebilitating symptomsImpact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
Sahyoun L, Fetene J, McMillan C, Protiva P, Al Bawardy B, Gaidos J, Proctor D. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease. Digestive Diseases And Sciences 2024, 69: 1654-1660. PMID: 38466459, DOI: 10.1007/s10620-024-08355-3.Peer-Reviewed Original ResearchSevere COVID-19 infectionInflammatory bowel diseaseCOVID-19 infectionIBD flareIBD therapyCOVID-19 treatmentSingle-center retrospective study of adult patientsMethodsA single-center retrospective studyAdvanced therapiesRetrospective study of adult patientsBowel diseaseStudy of adult patientsInflammatory bowel disease therapyDevelopment of severe COVID-19 infectionSevere COVID-19Acute COVID-19Corticosteroid useNo significant differenceNo therapyAdult patientsSupplemental oxygenPrimary outcomeSecondary outcomesTherapyCorticosteroidsDNA methylation in long COVID
Xiao Y, Vermund S. DNA methylation in long COVID. Frontiers In Virology 2024, 4: 1371683. DOI: 10.3389/fviro.2024.1371683.Peer-Reviewed Original ResearchDNA methylationSevere acute respiratory syndromeAcute coronavirus disease 2019Middle East respiratory syndromeLong-term sequelaeDNA methylation phenomenonLong COVIDPredictive of outcomeCombination of clinical signsAcute COVID-19DNA methylation markersVirus-host interactionsLong lasting persistenceSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Respiratory syndromeChronic symptomsEpigenetic phenomenaSyndrome coronavirus 2Evolving syndromeCoronavirus disease 2019Long COVID patientsSyndromeAcute respiratory syndrome
2023
COVID-19 Convalescent Plasma Therapy: Long-term Implications
Yoon H, Li Y, Goldfeld K, Cobb G, Sturm-Reganato C, Ostrosky-Zeichner L, Jayaweera D, Philley J, Desruisseaux M, Keller M, Hochman J, Pirofski L, Ortigoza M, Hochman J, Cronstein B, Keeling D, Rappoport N, Saraga J, Holahan J, Ortigoza M, Pirofski L, Yoon H, Sturm-Reganato C, Cobb G, Andela R, Darwish Y, Taveras M, Xin P, LaFleur J, Cleare L, Goldfeld K, Li Y, Ortigoza M, O'Keeffe M, Cobb G, Sturm-Reganato C, Rahman F, Ajayi A, Rodriguez S, Iturrate E, Gallagher J, Thomas O, Ramos D, Fong C, Pirofski L, Yoon H, Keller M, Asencio A, Eke I, Castro J, Shan J, Chalco A, LaFleur J, Cleare L, Desruisseaux M, Cortezzo G, Rocco E, Ndunge O, Parmelee C, Solomon G, Cahil S, Jayaweera D, Lee C, Ransford D, Dasmany D, Corona A, Moreno K, Martinez G, Otero C, McPherson D, Ostrosky-Zeichner L, Patel B, Nigo M, Huebinger R, Dronavalli G, Grimes C, Umana V, Hernandez M, Nielsen L, Stutz T, Mammadova M, Dentino A, Heath T, Martin J, Bello F, Hinojosa E, Philley J, Devine M, Hibbard R, Ford A. COVID-19 Convalescent Plasma Therapy: Long-term Implications. Open Forum Infectious Diseases 2023, 11: ofad686. PMID: 38269049, PMCID: PMC10807994, DOI: 10.1093/ofid/ofad686.Peer-Reviewed Original ResearchPost-acute sequelaePROMIS scoresCOVID-19 convalescent plasma (CCP) therapySARS-CoV-2 infection symptomsSARS-CoV-2 infectionAcute COVID-19Convalescent plasma therapyGlobal health assessmentPhysical health scoresCOVID-19 hospitalizationCOVID-19 trialsSelf-reported symptomsRespective reference groupsRace/ethnicityPASC symptomsRandomization armAcute infectionAcute treatmentPlasma therapyGeneral symptomsSymptom SurveyLong-term effectsHealth scoresOverall healthDisease severityEffectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
Ioannou G, Berry K, Rajeevan N, Li Y, Mutalik P, Yan L, Bui D, Cunningham F, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Osborne T, Viglianti E, Aslan M, Huang G, Bajema K. Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation. Annals Of Internal Medicine 2023, 176: 1486-1497. PMID: 37903369, PMCID: PMC10620954, DOI: 10.7326/m23-1394.Peer-Reviewed Original ResearchConceptsAcute COVID-19Veterans Health AdministrationUntreated comparatorsThromboembolic eventsCOVID-19Severe COVID-19Target trial emulationSARS-CoV-2Post COVID-19 conditionIndex dateVenous thromboembolismBaseline characteristicsCumulative incidencePulmonary embolismAcute infectionMedian ageOral antiviralsTrial emulationVHA careOutpatient treatmentInternational ClassificationHealth AdministrationU.S. veteransVeterans AffairsOrgan systemsLate Mortality After COVID-19 Infection Among US Veterans vs Risk-Matched Comparators
Iwashyna T, Seelye S, Berkowitz T, Pura J, Bohnert A, Bowling C, Boyko E, Hynes D, Ioannou G, Maciejewski M, O’Hare A, Viglianti E, Womer J, Prescott H, Smith V, Admon A, Akgun K, Anderson S, Aslan M, Au D, Backus L, Bajema K, Baraff A, Batten L, Berkowitz T, Bernstein T, Berry Wyatt K, Bogdan J, Bosworth H, Boucher N, Burwick N, Cabrales A, Cano J, Chai W, Chen J, Cheung K, Crothers K, Curtis J, Davis M, Del Monico E, Dobalian A, Doll J, Dominitz J, Eastment M, Fan V, Ferguson J, Floyd B, Fox A, Goetz M, Govier D, Green P, Hastings S, Hauschildt K, Hawkins E, Hebert P, Helfand M, Hickok A, Horowitz D, Hough C, Hu E, Ikuta K, Jones B, Jones M, Kamphuis L, Kaufman B, Knight S, Korpak A, Korpela P, Kumbier K, Langa K, Laundry R, Lavin S, Li Y, Linquist J, McCready H, Michel M, Miles A, Milne J, Monahan M, Morelli D, Mutalik P, Naylor J, Neiderhausen M, Newell S, Nugent S, Ong M, Osborne T, Peterson M, Peterson A, Rajeevan N, Reddy A, Rouse M, Rowneki M, Saha S, Saini S, Shah J, Shahoumian T, Shaukat A, Shepherd-Banigan M, Showalter W, Slatore C, Smith N, Smith B, Suri P, Sussman J, Takata Y, Teo A, Thomas E, Thomas L, Tuepker A, Veigulis Z, Vig E, Vranas K, Wang X, Wicks K, Winchell K, Wong E, Woods C, Wysham K, Yan L, Zulman D. Late Mortality After COVID-19 Infection Among US Veterans vs Risk-Matched Comparators. JAMA Internal Medicine 2023, 183: 1111-1119. PMID: 37603339, PMCID: PMC10442778, DOI: 10.1001/jamainternmed.2023.3587.Peer-Reviewed Original ResearchCOVID-19 infectionAdjusted hazard ratioRetrospective cohort studyUninfected comparatorsLate mortalityCohort studyHazard ratioMortality riskCOVID-19Acute COVID-19Excess mortality riskUnadjusted mortality ratesVeterans Affairs hospitalCOVID-19 persistHealth record dataCause mortalityCox regressionUS veteransExcess mortalityDay 180Mortality rateUninfected individualsPrimary analysisDay 91Excess deathsImaging Acute and Chronic Cardiac Complications of COVID-19 and after COVID-19 Vaccination.
Sánchez Tijmes F, Marschner C, de Matos J, Urzua Fresno C, Gutiérrez Chacoff J, Thavendiranathan P, Fuss C, Hanneman K. Imaging Acute and Chronic Cardiac Complications of COVID-19 and after COVID-19 Vaccination. RadioGraphics 2023, 43: e230044. PMID: 37616171, DOI: 10.1148/rg.230044.Peer-Reviewed Original ResearchConceptsLate gadolinium enhancementGadolinium enhancementCardiac MRICOVID-19 vaccinePattern of late gadolinium enhancementCardiac complications of COVID-19MRNA-based COVID-19 vaccinesPresence of cardiovascular diseaseStress-induced cardiomyopathyMultimodality cardiac imagingBasal inferolateral wallMinority of patientsPersistent cardiac symptomsAdverse cardiovascular eventsComplications of COVID-19Chronic cardiac complicationsManifestations of COVID-19Potential mechanisms of injuryMechanism of injuryCardiovascular manifestations of COVID-19Messenger ribonucleic acidAcute COVID-19Cardiac symptomsCardiovascular manifestationsImaging findingsComputational Prediction of the Interaction of Ivermectin with Fibrinogen
Vottero P, Tavernini S, Santin A, Scheim D, Tuszynski J, Aminpour M. Computational Prediction of the Interaction of Ivermectin with Fibrinogen. International Journal Of Molecular Sciences 2023, 24: 11449. PMID: 37511206, PMCID: PMC10380762, DOI: 10.3390/ijms241411449.Peer-Reviewed Original ResearchConceptsSpike proteinSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Acute COVID-19Coagulation factor fibrinogenSyndrome coronavirus 2Interactions of ivermectinBlood coagulation factor fibrinogenSARS-CoV-2 spike proteinAbnormal blood clotsAntiparasitic drug ivermectinLong COVIDFactors fibrinogenCoronavirus 2Proinflammatory activityClot propertiesPathologic thrombosisClot formationBlood clotsDrug ivermectinIvermectinFibrinogen peptidesFibrin clotsCOVID-19Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19
Self W, Shotwell M, Gibbs K, de Wit M, Files D, Harkins M, Hudock K, Merck L, Moskowitz A, Apodaca K, Barksdale A, Safdar B, Javaheri A, Sturek J, Schrager H, Iovine N, Tiffany B, Douglas I, Levitt J, Busse L, Ginde A, Brown S, Hager D, Boyle K, Duggal A, Khan A, Lanspa M, Chen P, Puskarich M, Vonderhaar D, Venkateshaiah L, Gentile N, Rosenberg Y, Troendle J, Bistran-Hall A, DeClercq J, Lavieri R, Joly M, Orr M, Pulley J, Rice T, Schildcrout J, Semler M, Wang L, Bernard G, Collins S, Becker R, del Zoppo G, Henke P, Holubkov R, Johnson M, Kerr K, Lipman H, Lurie F, Pitt B, Vesely S, Fleg J, Aamodt D, Ayers J, Clark D, Collins J, Cook M, Dixon S, Graves J, Jordan C, Lindsell C, Lopez I, McKeel D, Orozco D, Prato N, Qi A, Qutab M, Stoughton C, Vermillion K, Walsh K, Winchell S, Young T, Franklin R, Wagner E, Walther T, Demitrack M, Johnson J, Walsh R, Bales B, Miller K, Torr D, Barot H, Landreth L, LaRose M, Parks L, Teixeira J, Cardenas S, Ceniceros J, Cunningham A, Kunkel S, Lovato D, Zimmerman B, Nguyen T, Zeger W, Nichols H, Wiedel N, Javaheri A, Stilinovic S, Brokowski C, Lu J, Solberg M, Lee D, Roach K, Tiffany B, Tanner C, Taylor A, Zumbahl J, Syed A, Mason J, Jackson P, Coleman R, Haughey H, Cherabuddi K, James N, Wakeman R, Duncan C, Montero C, Rogers A, Wilson J, Vojnik R, Perez C, Wyles D, Hiller T, Oakes J, Garcia A, Gong M, Mohamed A, Andrea L, Nair R, Nkemdirim W, Lopez B, Boujid S, Torres M, Garcia O, Martinez F, Baduashvili A, Bastman J, Chauhan L, Douin D, Finck L, Licursi A, ten Lohuis C, Zhang S, Bender W, Tovar S, Hayes S, Kurtzman N, Rosseto E, Scaffidi D, Shapiro N, Pak J, Allada G, Briceno G, Peña J, Oh M, Ali H, Beselman S, Eby Y, Klimov V, Hite R, Tanzeem H, Droege C, Winter J, Jackman S, Caudill A, Bayoumi E, Pascual E, Chen P, Mucha S, Thiruchelvam N, Siuba M, Mehkri O, Driver B, Hendrickson A, Kaus O, Ontiveros C, Riehm A, Laudun S, Hudock D, Ensley C, Shaner V, Gentile N, Isenberg D, Reimer H, Cincola P, Harris E, Callahan S, Yamane M, Barrios M, Desai N, Bharara A, Keller M, Majumder P, Dohe C, D’Armiento J, Goldklang M, Wagener G, Fonseca L, Valezquez-Sanchez I, Johnson N, Petersen E, Fuentes M, Newton M, Gundel S, Srinivasan V, Steel T, Robinson B. Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19. JAMA 2023, 329: 1170-1182. PMID: 37039791, PMCID: PMC10091180, DOI: 10.1001/jama.2023.3546.Peer-Reviewed Original ResearchConceptsAngiotensin II type 1 receptorII type 1 receptorRenin-angiotensin systemSevere COVID-19Type 1 receptorCause mortalityRAS agentsRAS modulationPlacebo groupAngiotensin IIIntravenous infusionOdds ratioSafety outcomesCOVID-19Renin-angiotensin system modulationSARS-CoV-2 infectionAcute COVID-19Key secondary outcomesAction of angiotensinKidney replacement therapySupplemental oxygen useCOVID-19 pathophysiologyContinuous intravenous infusionLast followSecondary outcomesSARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Jaycox J, Lucas C, Yildirim I, Dai Y, Wang E, Monteiro V, Lord S, Carlin J, Kita M, Buckner J, Ma S, Campbell M, Ko A, Omer S, Lucas C, Speake C, Iwasaki A, Ring A. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Nature Communications 2023, 14: 1299. PMID: 36894554, PMCID: PMC9996559, DOI: 10.1038/s41467-023-36686-8.Peer-Reviewed Original ResearchConceptsVaccine-associated myocarditisAutoimmune patientsAutoantibody reactivitySARS-CoV-2 mRNA vaccinationVaccine-related adverse effectsSARS-CoV-2 immunitySARS-CoV-2 infectionAcute COVID-19Development of autoantibodiesCOVID-19 patientsAnti-viral immunityVirus-specific antibodiesCOVID-19 vaccineCOVID-19Humoral autoimmunityMRNA vaccinationAutoantibody responsePost vaccinationAutoantibody developmentAutoimmune diseasesHumoral responseHealthy individualsPatientsAntigen profilingAdverse effects
2022
Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae
Thompson R, Simons N, Wilkins L, Cheng E, Del Valle D, Hoffman G, Cervia C, Fennessy B, Mouskas K, Francoeur N, Johnson J, Lepow L, Le Berichel J, Chang C, Beckmann A, Wang Y, Nie K, Zaki N, Tuballes K, Barcessat V, Cedillo M, Yuan D, Huckins L, Roussos P, Marron T, Glicksberg B, Nadkarni G, Heath J, Gonzalez-Kozlova E, Boyman O, Kim-Schulze S, Sebra R, Merad M, Gnjatic S, Schadt E, Charney A, Beckmann N. Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae. Nature Medicine 2022, 29: 236-246. PMID: 36482101, PMCID: PMC9873574, DOI: 10.1038/s41591-022-02107-4.Peer-Reviewed Original ResearchConceptsImmunoglobulin-related genesPost-acute sequelaeAdaptive immune cellsTiter-dependent mannerLong-term sequelaeGene expression signaturesSARS-CoV-2 infectionAcute COVID-19Acute host responseImmune cellsAcute infectionSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2External cohortMultiple etiologiesSequelaePost-acute sequelae of severe acute respiratory syndrome coronavirus 2Molecular etiologyTranscriptome-wide investigationSyndrome coronavirus 2Expression signaturesHost responseAntibody productionGene expression patternsBlood Transcriptomes of SARS-CoV-2–Infected Kidney Transplant Recipients Associated with Immune Insufficiency Proportionate to Severity
Sun Z, Zhang Z, Banu K, Al Azzi Y, Reghuvaran A, Fredericks S, Planoutene M, Hartzell S, Kim Y, Pell J, Tietjen G, Asch W, Kulkarni S, Formica R, Rana M, Maltzman JS, Zhang W, Akalin E, Heeger PS, Cravedi P, Menon MC. Blood Transcriptomes of SARS-CoV-2–Infected Kidney Transplant Recipients Associated with Immune Insufficiency Proportionate to Severity. Journal Of The American Society Of Nephrology 2022, 33: 2108-2122. PMID: 36041788, PMCID: PMC9678030, DOI: 10.1681/asn.2022010125.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsImmune activation pathwaysImmunosuppressant useKTR cohortAcute illnessBlood transcriptomeAcute casesT cellsCOVID-19Most kidney transplant recipientsPost-acute COVID-19Adaptive immune system activationManagement of immunosuppressionReinstitution of immunosuppressionAcute COVID-19Serum inflammatory cytokinesCOVID-19 severity scoreCOVID-19 infectionImmune system activationUpregulation of neutrophilActivation pathwayTransplant recipientsChart reviewImmune signaturesLymphocyte countCoronavirus disease 2019 and the young heart: prevention, treatment, and return to play
Beach CM, Faherty E, Pesce M. Coronavirus disease 2019 and the young heart: prevention, treatment, and return to play. Current Opinion In Pediatrics 2022, 34: 471-475. PMID: 36036422, PMCID: PMC9593324, DOI: 10.1097/mop.0000000000001167.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCOVID-19 vaccinationRisk factorsSevere diseasePhysical activitySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmissionAcute COVID-19 infectionAcute COVID-19Regular physical activityViral prevalenceCOVID-19 infectionSpecific risk factorsCoronavirus disease 2019Current care modelsPrevention of diseaseInflammatory syndromeCardiac manifestationsPoor outcomeDisease 2019Care modelYoung heartsViral transmissionInfectionDiseaseCOVID-19VaccinationIntersecting Pandemics of HIV and SARS-CoV-2: Commentary on the Special Issue
Vermund SH. Intersecting Pandemics of HIV and SARS-CoV-2: Commentary on the Special Issue. Current HIV/AIDS Reports 2022, 19: 1-4. PMID: 35192108, PMCID: PMC8862004, DOI: 10.1007/s11904-022-00599-w.Peer-Reviewed Original ResearchA comparison of pulmonary embolism in pediatric and adult patients with acute COVID-19
Hodes A, Villasana-Gomez G, Traube L, Kurian J, Liszewski M, Lazarus M, Levin T, Blumfield E. A comparison of pulmonary embolism in pediatric and adult patients with acute COVID-19. Clinical Imaging 2022, 85: 10-13. PMID: 35220003, PMCID: PMC8863304, DOI: 10.1016/j.clinimag.2022.02.015.Peer-Reviewed Original ResearchConceptsAcute COVID-19COVID-19 pediatric patientsPulmonary embolismPediatric patientsAdult patientsPE rateUnderwent CTPACOVID-19Adult cohortRate of PEAcute COVID-19 patientsCOVID-19 adultsD-dimer levelsCOVID-19 patientsDiabetes mellitusRetrospective reviewPediatric groupCTPA studiesCT pulmonaryPatientsAdult groupCTPAChest radiologistsStudy periodEmbolismA Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020
Schuster JE, Halasa NB, Nakamura M, Levy ER, Fitzgerald JC, Young CC, Newhams MM, Bourgeois F, Staat MA, Hobbs CV, Dapul H, Feldstein LR, Jackson AM, Mack EH, Walker TC, Maddux AB, Spinella PC, Loftis LL, Kong M, Rowan CM, Bembea MM, McLaughlin GE, Hall MW, Babbitt CJ, Maamari M, Zinter MS, Cvijanovich NZ, Michelson KN, Gertz SJ, Carroll CL, Thomas NJ, Giuliano JS, Singh AR, Hymes SR, Schwarz AJ, McGuire JK, Nofziger RA, Flori HR, Clouser KN, Wellnitz K, Cullimore ML, Hume JR, Patel M, Randolph AG, Investigators O. A Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020. Journal Of The Pediatric Infectious Diseases Society 2022, 11: piab123-. PMID: 35022779, PMCID: PMC8807297, DOI: 10.1093/jpids/piab123.Peer-Reviewed Original ResearchConceptsCOVID-19-directed therapiesAcute coronavirus disease 2019Life-threatening COVID-19COVID-19Acute COVID-19Underlying medical conditionsIntensive care unitHigh-acuity careCoronavirus disease 2019Half of childrenYears of ageCharacteristics of childrenRemdesivir useSystemic steroidsRespiratory supportClinical courseCare unitPediatric hospitalSpecific therapyPediatric dataIll childrenLaboratory valuesDisease 2019Medical conditionsUS hospitals
2021
Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination
Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS, Shaughnessy R, Caron R, Fuss C, Corbin KJE, Emuren L, Faherty E, Hall EK, Di Pentima C, Oster ME, Paintsil E, Siddiqui S, Timchak DM, Guzman-Cottrill JA. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. Pediatrics 2021, 148: e2021052478. PMID: 34088762, DOI: 10.1542/peds.2021-052478.Peer-Reviewed Original ResearchConceptsPfizer-BioNTech COVID-19 vaccinationCOVID-19 vaccinationAcute myocarditisClinical courseLate gadolinium enhancement (LGE) characteristicsPolymerase chain reaction test resultsTranscription polymerase chain reaction (RT-PCR) test resultsVaccine Adverse Event Reporting SystemCoronavirus disease 2019 (COVID-19) vaccinationAcute COVID-19Multisystem inflammatory syndromeAdverse Event Reporting SystemImportant adverse eventsTime of presentationNonsteroidal antiinflammatory drugsHealthy male adolescentsGadolinium enhancement characteristicsEvent Reporting SystemReaction test resultsChest painElevated troponinInflammatory syndromeIntravenous immunoglobulinAdverse eventsSecond doseData-driven clustering identifies features distinguishing multisystem inflammatory syndrome from acute COVID-19 in children and adolescents
Geva A, Patel MM, Newhams MM, Young CC, Son MBF, Kong M, Maddux AB, Hall MW, Riggs BJ, Singh AR, Giuliano JS, Hobbs CV, Loftis LL, McLaughlin GE, Schwartz SP, Schuster JE, Babbitt CJ, Halasa NB, Gertz SJ, Doymaz S, Hume JR, Bradford TT, Irby K, Carroll CL, McGuire JK, Tarquinio KM, Rowan CM, Mack EH, Cvijanovich NZ, Fitzgerald JC, Spinella PC, Staat MA, Clouser KN, Soma VL, Dapul H, Maamari M, Bowens C, Havlin KM, Mourani PM, Heidemann SM, Horwitz SM, Feldstein LR, Tenforde MW, Newburger JW, Mandl KD, Randolph AG, Investigators O. Data-driven clustering identifies features distinguishing multisystem inflammatory syndrome from acute COVID-19 in children and adolescents. EClinicalMedicine 2021, 40: 101112. PMID: 34485878, PMCID: PMC8405351, DOI: 10.1016/j.eclinm.2021.101112.Peer-Reviewed Original ResearchSARS-CoV-2 PCRCluster 1 patientsInflammatory syndromeClinical featuresPositive SARS-CoV-2 PCRAcute COVID-19 pneumoniaCOVID-19 pulmonary diseaseCOVID-19-related illnessChest radiograph infiltratesHigher inflammatory biomarkersPositive PCR testingAcute COVID-19Multisystem inflammatory syndromeCOVID-19 pneumoniaDiagnosis of MISCluster 3 patientsCluster 2 patientsClusters of patientsPre-existing conditionsPulmonary infiltratesInflammatory biomarkersMucocutaneous involvementPulmonary diseaseRadiographic findingsMean ageImmuno-fibrotic drivers of impaired lung function in post-acute sequelae of SARS-CoV-2
Chun HJ, Coutavas E, Pine AB, Lee AI, Yu VL, Shallow MK, Giovacchini CX, Mathews AM, Stephenson B, Que LG, Lee PJ, Kraft BD. Immuno-fibrotic drivers of impaired lung function in post-acute sequelae of SARS-CoV-2. JCI Insight 2021, 6: e148476. PMID: 34111030, PMCID: PMC8410030, DOI: 10.1172/jci.insight.148476.Peer-Reviewed Original ResearchConceptsCOVID-19 severityIntensive care unitCOVID-19 illnessRespiratory symptomsLipocalin-2Acute COVID-19 illnessSARS-CoV-2 infectionCOVID-19Acute COVID-19Mild COVID-19Prospective cohort studyPulmonary function testsPost-acute sequelaeAmerican Heart AssociationHost response profileSeparate validation cohortAcademic medical centerSARS-CoV-2Plasma biomarker profilesICU groupLung recoveryCohort studyExpiratory volumeLung impairmentPersistent symptomsClinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY
Walker AJ, MacKenna B, Inglesby P, Tomlinson L, Rentsch CT, Curtis HJ, Morton CE, Morley J, Mehrkar A, Bacon S, Hickman G, Bates C, Croker R, Evans D, Ward T, Cockburn J, Davy S, Bhaskaran K, Schultze A, Williamson EJ, Hulme WJ, McDonald HI, Mathur R, Eggo RM, Wing K, Wong AY, Forbes H, Tazare J, Parry J, Hester F, Harper S, O’Hanlon S, Eavis A, Jarvis R, Avramov D, Griffiths P, Fowles A, Parkes N, Douglas IJ, Evans SJ, Smeeth L, Goldacre B, . Clinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY. British Journal Of General Practice 2021, 71: bjgp.2021.0301. PMID: 34340970, PMCID: PMC8340730, DOI: 10.3399/bjgp.2021.0301.Peer-Reviewed Original ResearchConceptsLong COVIDEnglish primary carePrimary careDiagnostic codesPopulation-based cohort studyAcute COVID-19Different diagnostic thresholdsProportion of peoplePlanning of servicesPersistent symptomsCohort studyGeneral practiceClinicians' understandingDiagnostic thresholdNHS EnglandPatient recordsClinical codesClinical codingCareCOVID-19East of EnglandPatientsDemographic factorsCOVIDWeeks
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply